© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 90650 refers to the Human Papillomavirus (HPV) vaccine, specifically the bivalent formulation that targets types 16 and 18. This vaccine is administered via intramuscular injection and is designed to be given in a three-dose schedule. Vaccines, unlike immune globulins, provide long-term immunity by stimulating the recipient's immune system to recognize and combat specific pathogens. In this case, the HPV vaccine exposes the immune system to an altered version of the virus, prompting the production of antibodies that will protect against future infections. The HPV virus comprises over 100 different types, some of which can lead to benign warts, while others, particularly the high-risk strains, are associated with the development of cervical cancer. The administration of this vaccine is most effective when given before the individual has been exposed to the virus, thereby preventing potential infections and their serious long-term consequences, such as cancer. It is important to note that this code specifically reports the supply of the bivalent vaccine product, distinguishing it from other HPV vaccines such as the quadrivalent (4vHPV) and nonavalent (9vHPV) vaccines, which target additional strains associated with various cancers.
© Copyright 2025 Coding Ahead. All rights reserved.
The Human Papillomavirus vaccine, CPT® Code 90650, is indicated for the prevention of infections caused by specific high-risk types of HPV, particularly types 16 and 18, which are known to be associated with cervical cancer. The vaccine is recommended for individuals who have not yet been exposed to these strains of the virus, making it most effective when administered prior to the onset of sexual activity. The primary goal of the vaccine is to provide long-term immunity against these high-risk HPV types, thereby reducing the incidence of cervical cancer and other HPV-related diseases.
The administration of the Human Papillomavirus vaccine, CPT® Code 90650, follows a structured three-dose schedule. Each dose is delivered via intramuscular injection, typically in the deltoid muscle of the upper arm. The first dose is administered at a designated time, followed by the second dose given 1 to 2 months later, and the third dose is administered 6 months after the first dose. This schedule is crucial for ensuring the development of adequate immunity against the virus. It is important for healthcare providers to monitor the patient for any immediate adverse reactions following the injection, as well as to provide education on the importance of completing the full vaccination series to achieve optimal protection against HPV-related diseases.
After the administration of the Human Papillomavirus vaccine, patients are typically advised to remain in the healthcare setting for a short period to monitor for any immediate adverse reactions, such as allergic responses. Common side effects may include pain at the injection site, mild fever, or fatigue. Patients should be educated on the importance of completing the entire three-dose series to ensure full protection against HPV. Additionally, follow-up appointments should be scheduled to administer the subsequent doses according to the recommended timeline. It is also essential to inform patients that while the vaccine significantly reduces the risk of cervical cancer, it does not eliminate the need for regular cervical cancer screenings, such as Pap tests, as part of their ongoing healthcare routine.
| Short Descr | 2VHPV VACCINE 3 DOSE IM | Medium Descr | 2VHPV VACCINE 3 DOSE SCHEDULE FOR IM USE | Long Descr | Human Papillomavirus vaccine, types 16, 18, bivalent (2vHPV), 3 dose schedule, for intramuscular use | Status Code | Excluded from Physician Fee Schedule by Regulation | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Items and Services Not Billable to the MAC | Type of Service (TOS) | 1 - Medical Care | Berenson-Eggers TOS (BETOS) | O1G - Immunizations/Vaccinations | MUE | 1 | CCS Clinical Classification | 228 - Prophylactic vaccinations and inoculations |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2016-01-01 | Changed | First appearance of change in codebook. |
| 2015-07-01 | Changed | Description Changed. |
| 2011-01-01 | Changed | FDA Approval Pending status changed. Medium description changed. Short description changed. |
| 2009-01-01 | Added | First appearance in code book in 2009. |
| 2008-01-01 | Added | Added |
| 1991-12-31 | Deleted | Code deleted. |
Get instant expert-level medical coding assistance.